A Phase III, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Oral MK0974 [telcagepant] in the Acute Treatment of Migraine With or Without Aura

Trial Profile

A Phase III, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Oral MK0974 [telcagepant] in the Acute Treatment of Migraine With or Without Aura

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jun 2014

At a glance

  • Drugs Telcagepant (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Acronyms COMPLETED
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 04 Jul 2012 Planned number of patients changed from 1575 to 1600 as reported by European Clinical Trials Database.
    • 07 Aug 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 27 Dec 2007 The expected completion date for this trial is now 1 Dec 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top